{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:45:32Z","timestamp":1761518732745},"reference-count":31,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2004,3,1]],"date-time":"2004-03-01T00:00:00Z","timestamp":1078099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":5790,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2004,3]]},"DOI":"10.1093\/annonc\/mdh107","type":"journal-article","created":{"date-parts":[[2004,3,3]],"date-time":"2004-03-03T19:13:19Z","timestamp":1078341199000},"page":"433-439","source":"Crossref","is-referenced-by-count":33,"title":["A randomized phase II study of combination, alternating and sequential regimens of doxorubicin and docetaxel as first-line chemotherapy for women with metastatic breast cancer"],"prefix":"10.1016","volume":"15","author":[{"given":"S.","family":"Cresta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Grasselli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Mansutti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Martoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Lelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Capri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Buzzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Robustelli Della Cuna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Jirillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Terzoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Frevola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Tarenzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Sguotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Azli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Murawsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Gianni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdh107_bb0010","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1200\/JCO.1989.7.5.560","article-title":"Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer","volume":"7","author":"Henderson","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh107_bb0015","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1093\/oxfordjournals.annonc.a010544","article-title":"A multicentre phase II study of the efficacy and safety of docetaxel as first line treatment of advanced breast cancer: report of the EORTC","volume":"7","author":"Fumoleau","year":"1996","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdh107_bb0020","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1200\/JCO.1999.17.8.2341","article-title":"Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer","volume":"17","author":"Chan","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh107_bb0025","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1200\/JCO.1995.13.12.2879","article-title":"Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer","volume":"13","author":"Ravdin","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh107_bb0030","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1023\/A:1026418831238","article-title":"Dose-finding study of docetaxel and doxorubicin in first-line treatment of patients with metastatic breast cancer","volume":"10","author":"Misset","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdh107_bb0035","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1200\/JCO.2001.19.2.314","article-title":"Phase II study of docetaxel, doxorubicin, and cyclophosphamide as first line chemotherapy for metastatic breast cancer","volume":"19","author":"Nabholtz","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh107_bb0040","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1200\/JCO.2003.04.040","article-title":"Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial","volume":"21","author":"Nabholtz","year":"2003","journal-title":"J Clin Oncol"},{"issue":"Abstr 137","key":"10.1093\/annonc\/mdh107_bb0045","first-page":"21","article-title":"Final results of the phase III randomized trial comparing docetaxel, doxorubicin and cyclophosphamide to FAC as first line chemotherapy for patients with metastatic breast cancer","volume":"35a","author":"Mackey","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"Abstr 141","key":"10.1093\/annonc\/mdh107_bb0050","first-page":"21","article-title":"Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer patients: interim analysis of the BCIRG 001","volume":"36a","author":"Nabholtz","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdh107_bb0055","first-page":"439","article-title":"Rationale for the use of alternating non-cross-resistant chemotherapy","volume":"66","author":"Goldie","year":"1982","journal-title":"Cancer Treat Rep"},{"key":"10.1093\/annonc\/mdh107_bb0060","first-page":"1307","article-title":"Tumor size, sensitivity to therapy, and the design of treatment schedules","volume":"61","author":"Norton","year":"1977","journal-title":"Cancer Treat Rep"},{"key":"10.1093\/annonc\/mdh107_bb0065","first-page":"76","article-title":"An Overview of Recent and Ongoing Adjuvant Clinical Trials for Breast Cancer","author":"Piccart","year":"2002"},{"key":"10.1093\/annonc\/mdh107_bb0070","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1093\/oxfordjournals.annonc.a058514","article-title":"Drugs ten years later: epirubicin","volume":"4","author":"Bonadonna","year":"1993","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdh107_bb0075","year":"1979"},{"key":"10.1093\/annonc\/mdh107_bb0080","article-title":"Common Toxicity Criteria (CTC) version 20 highlights and tools","volume":"12","author":"Arbuck","year":"1998","journal-title":"10th NCIEORTC Symposium on New Drugs in Cancer Therapy"},{"key":"10.1093\/annonc\/mdh107_bb0085","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1200\/JCO.2000.18.12.2369","article-title":"Phase II trial of doxorubicin and docetaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: Eastern Cooperative Oncology Group Study E1196","volume":"18","author":"Sparano","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh107_bb0090","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1001\/jama.1995.03520310040027","article-title":"Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten years results","volume":"273","author":"Bonadonna","year":"1995","journal-title":"JAMA"},{"key":"10.1093\/annonc\/mdh107_bb0095","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1200\/JCO.1995.13.11.2688","article-title":"Paclitaxel by 3-hours infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study","volume":"13","author":"Gianni","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh107_bb0100","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1200\/JCO.1994.12.9.1764","article-title":"Phase II trial of vinorelbine\/doxorubicin as first line therapy of advanced breast cancer","volume":"12","author":"Spielmann","year":"1994","journal-title":"J Clin Oncol"},{"issue":"Abstr 226","key":"10.1093\/annonc\/mdh107_bb0105","first-page":"50","article-title":"Phase II study docetaxel in combination with doxorubicin as 1st line chemotherapy of metastatic breast cancer","volume":"262","author":"Dieras","year":"1998","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdh107_bb0110","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1200\/JCO.1999.17.10.3033","article-title":"Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: a randomized pilot trial of the Hoosier Oncology Group","volume":"17","author":"Miller","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh107_bb0115","article-title":"Preliminary results of a phase II randomized trial of taxotere and doxorubicin given in combination or sequentially as first line chemotherapy for metastatic breast cancer","volume":"20","author":"Koroleva","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdh107_bb0120","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/annonc\/mdg111","article-title":"A randomized phase II study of alternating and sequential regimens of docetaxel and doxorubicin as first-line chemotherapy for metastatic breast cancer","volume":"14","author":"Paridaens","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdh107_bb0125","series-title":"Cancer. Principles and Practice of Oncology","first-page":"431","article-title":"Antimicrotubule agents","author":"Rowinsky","year":"2001"},{"key":"10.1093\/annonc\/mdh107_bb0130","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1200\/JCO.1999.17.7.1999","article-title":"Maximized reduction of primary breast cancer tumor size using preoperative chemotherapy with doxorubicin and docetaxel","volume":"17","author":"von Minckwitz","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdh107_bb0135","first-page":"4082","article-title":"Study of dose escalation and sequence switching of administration of the combination of docetaxel and doxorubicin in advanced breast cancer","volume":"6","author":"Itoh","year":"2000","journal-title":"Clin Cancer Res"},{"issue":"Suppl 6","key":"10.1093\/annonc\/mdh107_bb0140","first-page":"25","article-title":"Docetaxel\/doxorubicin\/cyclophosphamide in the treatment of metastatic breast cancer","volume":"11","author":"Nabholtz","year":"1997","journal-title":"Oncology (Huntingt)"},{"issue":"Suppl 13","key":"10.1093\/annonc\/mdh107_bb0145","first-page":"16","article-title":"Taxoids in combination with anthracyclines and other agents: pharmacokinetic considerations","volume":"25","author":"D\u2019Incalci","year":"1998","journal-title":"Sem Oncol"},{"key":"10.1093\/annonc\/mdh107_bb0150","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1056\/NEJM199809243391307","article-title":"Doxorubicin-induced cardiomyopathy","volume":"339","author":"Singai","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdh107_bb0155","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1023\/A:1008309916974","article-title":"Pharmacokinetic interactions of paclitaxel, docetaxel and their vehicles with doxorubicin","volume":"10","author":"Colombo","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdh107_bb0160","first-page":"1511","article-title":"Paclitaxel and docetaxel enhance the metabolism of doxorubicin to toxic species in human myocardium","volume":"7","author":"Minotti","year":"2001","journal-title":"Clin Cancer Res"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419641530?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419641530?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/15\/3\/433\/558796\/mdh107.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T02:15:51Z","timestamp":1582251351000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419641530"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,3]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,3]]}},"alternative-id":["S0923753419641530"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdh107","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2004,3]]}}}